CN110183516B - Preparation method of blood pressure lowering ginkgo nut protein peptide - Google Patents
Preparation method of blood pressure lowering ginkgo nut protein peptide Download PDFInfo
- Publication number
- CN110183516B CN110183516B CN201910434381.7A CN201910434381A CN110183516B CN 110183516 B CN110183516 B CN 110183516B CN 201910434381 A CN201910434381 A CN 201910434381A CN 110183516 B CN110183516 B CN 110183516B
- Authority
- CN
- China
- Prior art keywords
- ginkgo
- protein
- blood pressure
- ginkgo nut
- protein peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a preparation method of a ginkgo nut protein peptide for reducing blood pressure. The method comprises the following specific steps: shelling fresh ginkgo nuts, and extracting crude protein after crushing treatment; carrying out enzymolysis on crude protein by protease; performing ultrafiltration on the enzymolysis liquid; subjecting the ultrafiltration permeate to Sephadex chromatography; separating the chromatographic solution by liquid chromatography to obtain the ginkgo protein peptide with the potential of reducing blood pressure, wherein the amino acid sequence of the ginkgo protein peptide is as follows: threonine-asparagine-leucine-aspartate-tryptophan-Tyrosine (TNLDWY). The small peptide prepared by the invention has high Angiotensin Converting Enzyme (ACE) inhibitory activity, does not have cysteine residue in an amino acid sequence, does not need to be added with an additive for protecting active peptide, has simple preparation process, low cost and high product quality, and is suitable for industrial production.
Description
Technical Field
The invention relates to a preparation method of a ginkgo nut protein peptide for reducing blood pressure, belonging to the technical field of deep processing of agricultural products.
Background
According to the estimation of the world health organization, 1750 million people die from cardiovascular diseases every year, and hypertension is the key point for preventing and treating the cardiovascular diseases. Currently used hypotensive drugs such as captopril and enalapril are limited due to adverse reactions such as cough, rash and headache. However, the incidence of cardiovascular disease is increasing and new, safe alternatives, such as food-derived active peptides, are needed. Bioactive peptides are a generic term for a series of polypeptides of different sequences that constitute natural amino acids. They have various biological functions such as antioxidation, immune promotion, hormone regulation, antibiosis, antithrombotic, antivirus, antihypertensive, etc. The antihypertensive peptide, also called angiotensin converting enzyme inhibitory peptide, is a short-chain polypeptide substance which is separated from food protein and has obvious blood pressure reducing effect. The in vitro hypotensive activity of polypeptides is determined primarily by measuring the inhibitory activity of Angiotensin Converting Enzyme (ACE). Angiotensin Converting Enzyme (ACE) is a dipeptidyl carboxypeptidase located on the cell membrane and a key molecule in regulating blood pressure. The antihypertensive peptide has high food safety and bioavailability, and is a potential choice for developing functional peptide drugs and functional food additives.
Disclosure of Invention
The invention aims to provide a preparation method of a ginkgo nut protein peptide for reducing blood pressure.
In order to achieve the above objects and other related objects, the present invention provides the following technical solutions: the ginkgo nut protein peptide for reducing blood pressure consists of the following amino acid residues: threonine-asparagine-leucine-aspartate-tryptophan-Tyrosine (TNLDWY).
In order to achieve the above objects and other related objects, the present invention provides the following technical solutions: a preparation method of a ginkgo nut protein peptide for reducing blood pressure comprises the following steps:
step 1; soaking and degreasing the ginkgo nut powder to obtain degreased ginkgo nut powder;
step 2: extracting protein from defatted ginkgo nut powder by an alkali-soluble acid precipitation method, dialyzing the obtained extracting solution, and freeze-drying to obtain ginkgo protein;
and step 3: preparing protein into aqueous solution, adding alkaline protease for enzymolysis, inactivating enzyme after enzymolysis, and centrifuging to obtain supernatant to obtain semen Ginkgo protease hydrolysate;
and 4, step 4: performing ultrafiltration treatment on the ginkgo protein hydrolysate, collecting ultrafiltration permeate and freeze-drying to obtain a ginkgo protein hydrolysate;
and 5: preparing semen Ginkgo protein hydrolysate into semen Ginkgo protein hydrolysate water solution, performing chromatography with dextran gel as chromatography medium, and collecting sample with retention time of 87.36-102.23 min;
step 6: desalting the sample obtained in the step 5, freeze-drying, dissolving in trifluoroacetic acid aqueous solution again, and then adopting a C18 reversed phase chromatographic column, wherein a mobile phase a is formic acid aqueous solution with the volume fraction of 0.1%, a mobile phase b is acetonitrile aqueous solution containing formic acid with the mass fraction of 0.1%, and the volume fraction of acetonitrile is 84%; after the chromatographic column is balanced by the solution a, a sample is loaded by an automatic sample injector, and the detection wavelength is 228 nm; collecting the eluate with peak time of 44.23 min to obtain semen Ginkgo protein peptide solution with blood pressure lowering effect; the mass spectrometry analysis result shows that the amino acid sequence of the ginkgo protein peptide is as follows: threonine-asparagine-leucine-aspartic acid-tryptophan-tyrosine.
The preferable technical scheme is as follows: step 1, soaking the ginkgo nut powder in ethyl acetate for degreasing, performing suction filtration to remove a solvent after degreasing is finished, and drying to obtain degreased ginkgo nut powder; the particle size of the ginkgo nut powder is less than or equal to 40-80 meshes.
The preferable technical scheme is as follows: and 2, dissolving the defatted ginkgo nut powder in distilled water, regulating the pH value to 10, stirring overnight, centrifuging, taking supernatant, regulating the pH value of the supernatant to 4.62, centrifuging again, removing the supernatant, taking precipitate, dialyzing the precipitate in distilled water, and freeze-drying to obtain the defatted ginkgo protein.
The preferable technical scheme is as follows: in step 3, the defatted ginkgo protein is prepared into protein aqueous solution, the pH value is adjusted to 10, then alkaline protease is added, and the temperature is kept at 48-52 ℃ for 3.5-4.5 h.
The preferable technical scheme is as follows: and 4, performing ultrafiltration treatment on the ginkgo biloba enzymolysis liquid by adopting an ultrafiltration membrane with the molecular weight cutoff of 3000 Da.
The preferable technical scheme is as follows: in step 5, performing chromatography on the ginkgo biloba protein hydrolysate solution by using a G-15 sephadex column, collecting a sample with the retention time of 87.36-102.23min, and taking ultrapure water as an eluent, wherein the flow rate is 1mL/min, and the sample loading concentration is 80 mg/mL.
Due to the application of the technical scheme, compared with the prior art, the invention has the advantages that:
the ginkgo protein peptide prepared by the invention has high Angiotensin Converting Enzyme (ACE) inhibitory activity, does not have cysteine residue in an amino acid sequence, does not need to be added with an additive for protecting active peptide, has simple preparation process, low cost and high product quality, and is suitable for industrial production.
Drawings
FIG. 1 is a graph of the chromatography of ginkgo biloba extract on Sephadex.
Detailed Description
The following description of the embodiments of the present invention is provided for illustrative purposes, and other advantages and effects of the present invention will become apparent to those skilled in the art from the present disclosure.
Please refer to fig. 1. It should be understood that the structures, ratios, sizes, and the like shown in the drawings and described in the specification are only used for matching with the disclosure of the specification, so as to be understood and read by those skilled in the art, and are not used to limit the conditions under which the present invention can be implemented, so that the present invention has no technical significance, and any structural modification, ratio relationship change, or size adjustment should still fall within the scope of the present invention without affecting the efficacy and the achievable purpose of the present invention. In addition, the terms "upper", "lower", "left", "right", "middle" and "one" used in the present specification are for clarity of description, and are not intended to limit the scope of the present invention, and the relative relationship between the terms and the terms is not to be construed as a scope of the present invention.
The blood pressure is reduced to investigate the ACE inhibitory activity, and the sample ACE inhibitory activity detection method comprises the following steps:
the substrate, hippuryl-histidine-leucine (HHL, 5 mM) and the sample were dissolved in 0.1M borate buffer (pH 8.3, containing 0.3M NaCl). Then, 50. mu.L of the sample and 150. mu.L of the substrate were added to the centrifuge tube, mixed and preheated in 37 ℃ water for 5 min. Then 0.1U of ACE solution was added and incubated at 37 ℃ for 60 min. At the end of the reaction 250. mu.L of 1M hydrochloric acid was added to terminate the reaction, and the solution was filtered through a 0.45 μ M filter and analyzed by reversed-phase high performance liquid chromatography on intsil ODS-3 (25X 4.6mm, 5 μ M particle size). The mobile phase was distilled water acetonitrile =75:25 (v/v, 0.1% trifluoroacetic acid), flow rate 0.5 mL/min, detection wavelength 228 nm. The inhibition activity (%) was determined using captopril as a positive control and distilled water as a blank control as follows:
ACE inhibitory activity (%) = [ (a-B)/a ] × 100;
a is the peak area of hippuric acid when blank control is used, and B is the peak area of hippuric acid when sample is contained.
Example 1: preparation method of blood pressure lowering ginkgo nut protein peptide
(1) Pretreatment of raw materials: 500 g of fresh ginkgo fruits are subjected to shelling, seed peeling treatment and cutting, the fresh ginkgo fruits are dried for 24 hours in a constant-temperature drying oven at 45 ℃, and the ginkgo fruits are sieved by a 60-mesh sieve after being crushed.
(2) Degreasing: soaking 220 g of ginkgo nut powder in 400mL of ethyl acetate, stirring once every 10min, soaking for 2h, performing suction filtration to remove the solvent, and drying to obtain defatted ginkgo nut powder;
(3) extracting ginkgo protein: dissolving 200g of defatted ginkgo powder in distilled water, adjusting the material-liquid ratio to be 1:15 and the pH value to be 10.0, stirring overnight, centrifuging 8000 g for 20 min, taking the supernatant, adjusting the pH value to be 4.62, centrifuging 8000 g for 20 min, discarding the supernatant, taking the precipitate, taking the distilled water as dialysate, dialyzing, and freeze-drying to obtain the ginkgo protein.
(4) Enzymolysis: preparing 200mL of 3% ginkgo protein aqueous solution, dissolving in 50 ℃ water bath, adjusting pH to 10.0, waiting for 5min, adding alkaline protease (enzyme activity 4000U), performing enzymolysis for 4h, adding NaOH solution during the enzymolysis, keeping the pH of the solution at 10.0, boiling for 5min to inactivate enzyme after enzymolysis is finished, cooling, adjusting pH to neutral, and centrifuging.
(5) And (3) ultrafiltration: and (3) carrying out ultrafiltration on 150 mL of enzymolysis liquid, wherein the interception amount is 3kDa, continuously collecting ultrafiltration components, and freeze-drying.
(6) Gel chromatography: preparing the product obtained in the step (5) into an aqueous solution, further purifying the ultrafiltration substance by using a G-15 sephadex column, taking ultrapure water as an eluent, wherein the flow rate is 1mL/min, the loading amount is 350mg, the loading volume is 4 mL, the loading concentration is 80 mg/mL, and collecting a chromatographic solution with the retention time of 87.36-102.23 min.
(7) The sample was desalted by chromatography on a DEAE cellulose column, then lyophilized and redissolved in 0.1% by volume trifluoroacetic acid solution. Then, a C18 reversed phase chromatographic column was used, and the mobile phase a was 0.1% formic acid aqueous solution, and the mobile phase b was 0.1% formic acid aqueous acetonitrile solution (acetonitrile 84%). After the column was equilibrated with 95% solution a, a sample was applied by an autosampler, and the detection wavelength was 228nm and the flow rate was 1 mL/min. Collecting eluate with peak time of 44.23 min to obtain semen Ginkgo protein peptide solution with blood pressure lowering (ACE inhibiting) activity. Mixing 0.1 mL formic acid and 99.9 mL distilled water, wherein the solution a is 'mobile phase a' -0.1% formic acid aqueous solution; mobile phase b-0.1% formic acid in acetonitrile in water, with a volume fraction of acetonitrile of 84%. Acetonitrile and water are mixed according to the volume ratio of 84:16 to prepare acetonitrile aqueous solution, and then 0.1 mL of formic acid and 99.9 mL of acetonitrile aqueous solution are mixed.
(8) And (3) determining the ACE inhibitory activity of the eluent, and detecting the amino acid sequence of the protein peptide by liquid chromatography-mass spectrometry.
The ACE inhibitory activity detection result is 54.75% (1 mg/mL), and the composition sequence of 44.23 min peak substances is analyzed by liquid chromatography-mass spectrometry: threonine-asparagine-leucine-aspartate-tryptophan-Tyrosine (TNLDWY).
Example 2: preparation method of blood pressure lowering ginkgo nut protein peptide
(1) Pretreatment of raw materials: 700g of fresh ginkgo fruits are subjected to shelling and seed peeling treatment, and then are placed in a constant temperature drying oven for drying for 30 hours, and are sieved by a 80-mesh sieve after being crushed.
(2) Degreasing: soaking 350 g of ginkgo nut powder in 100 mL of ethyl acetate, stirring once every 10min, soaking for 2h, performing suction filtration to remove the solvent, and drying to obtain defatted ginkgo nut powder;
(3) protein extraction: dissolving 300 g of defatted ginkgo powder in distilled water at a feed-liquid ratio of 1:18, adjusting pH to 10, placing on a magnetic stirrer, stirring for 6 h, centrifuging, collecting supernatant, performing acid precipitation, centrifuging, and freeze-drying to obtain ginkgo protein.
(4) Enzymolysis: preparing 250 mL of 3% protein solution, dissolving at 45 ℃, adjusting the pH value to 10.0, adding 3500U of alkaline protease, carrying out enzymolysis for 5 h, adding NaOH solution during the enzymolysis, keeping the pH value of the solution at 10.0, boiling for 10min to inactivate the enzyme after the enzymolysis is finished, cooling, adjusting the pH value back to 7, centrifuging, and freeze-drying.
(5) And (3) ultrafiltration: and (3) carrying out ultrafiltration on 200mL of enzymolysis liquid, wherein the interception amount is 3kDa, continuously collecting ultrafiltration components, and freeze-drying.
(6) Gel chromatography: the loading amount is 800mg, the loading volume is 10mL, and the chromatographic solution with the retention time of 87.36-102.23min is collected.
(7) The sample was desalted and lyophilized and then redissolved in 0.1% trifluoroacetic acid solution. The C18 reversed phase chromatographic column was adopted, and the mobile phase a was 0.1% formic acid aqueous solution, and the mobile phase b was acetonitrile aqueous solution containing 0.1% formic acid (acetonitrile 84%). After the column was equilibrated with 95% solution a, a sample was applied by an autosampler, and the detection wavelength was 228nm and the flow rate was 1 mL/min. Collecting eluate with peak time of 44.23 min;
(8) and (3) determining the ACE inhibitory activity of the eluent, and detecting the amino acid sequence of the protein peptide by liquid chromatography-mass spectrometry.
The ACE inhibitory activity detection result is 52.27% (1 mg/mL), and the composition sequence of 44.23 min peak substances is analyzed by liquid chromatography-mass spectrometry detection: threonine-asparagine-leucine-aspartate-tryptophan-Tyrosine (TNLDWY).
Example 3: preparation method of blood pressure lowering ginkgo nut protein peptide
The ginkgo nut protein peptide for reducing blood pressure consists of the following amino acid residues: threonine-asparagine-leucine-aspartate-tryptophan-Tyrosine (TNLDWY). .
The preparation method comprises the following steps:
step 1; soaking and degreasing the ginkgo nut powder to obtain degreased ginkgo nut powder;
step 2: extracting protein from defatted ginkgo nut powder by an alkali-soluble acid precipitation method, dialyzing the obtained extracting solution, and freeze-drying to obtain ginkgo protein;
and step 3: preparing protein into aqueous solution, adding alkaline protease for enzymolysis, inactivating enzyme after enzymolysis, and centrifuging to obtain supernatant to obtain semen Ginkgo protease hydrolysate;
and 4, step 4: performing ultrafiltration treatment on the ginkgo protein hydrolysate, collecting ultrafiltration permeate and freeze-drying to obtain a ginkgo protein hydrolysate;
and 5: performing chromatography on semen Ginkgo protein hydrolysate water solution (80 mg/mL) with dextran gel as chromatography medium, and collecting sample with retention time of 87.36-102.23 min;
step 6: subjecting the sample obtained in the step 5 to DEAE cellulose column chromatography desalination, freeze-drying, re-dissolving in trifluoroacetic acid aqueous solution with volume fraction of 0.1%, and then adopting a C18 reversed phase chromatographic column, wherein a mobile phase a is formic acid aqueous solution with mass fraction of 0.1%, a mobile phase b is acetonitrile aqueous solution containing formic acid with mass fraction of 0.1%, and the volume fraction of acetonitrile is 84%; after the chromatographic column is balanced by the solution a, a sample is loaded by an automatic sample injector; collecting eluate with peak time of 44.23 min to obtain semen Ginkgo protein peptide solution with ACE inhibitory activity. Mixing 0.1 mL formic acid and 99.9 mL distilled water, wherein the solution a is 'mobile phase a' -0.1% formic acid aqueous solution; mobile phase b-0.1% formic acid in acetonitrile in water, with a volume fraction of acetonitrile of 84%. Acetonitrile and water are mixed according to the volume ratio of 84:16 to prepare acetonitrile aqueous solution, and then 0.1 mL of formic acid and 99.9 mL of acetonitrile aqueous solution are mixed.
The preferred embodiment is: step 1, soaking the ginkgo nut powder in ethyl acetate for degreasing, performing suction filtration to remove a solvent after degreasing is finished, and drying to obtain degreased ginkgo nut powder; the particle size of the ginkgo nut powder is less than or equal to 40 meshes.
The preferred embodiment is: and 2, dissolving the defatted ginkgo nut powder in distilled water, adjusting the pH value to 10.0, stirring overnight, centrifuging, taking supernatant, adjusting the pH value of the supernatant to 4.62, centrifuging again, removing the supernatant, taking precipitate, dialyzing the precipitate in distilled water, and freeze-drying to obtain the defatted ginkgo protein.
The preferred embodiment is: in step 3, the defatted ginkgo protein is prepared into protein aqueous solution, the pH value is adjusted to 10, then alkaline protease is added, and the temperature is kept at 48 ℃ for 3.5 h.
And 4, performing ultrafiltration treatment on the ginkgo biloba enzymolysis liquid by adopting an ultrafiltration membrane with the molecular weight cutoff of 3000 Da.
The preferred embodiment is: in step 5, further purifying the ginkgo protein hydrolysate by using a G-15 sephadex column, wherein ultrapure water is used as an eluent, the flow rate is 1mL/min, and the sample loading concentration is 80 mg/mL.
Example 4: preparation method of blood pressure lowering ginkgo nut protein peptide
(1) Pretreatment: removing shell and peel of fresh semen Ginkgo, cutting, oven drying at 45 deg.C, pulverizing, and sieving with 50 mesh sieve;
(2) degreasing: soaking with ethyl acetate, stirring once every 10min, soaking for 2 hr, vacuum filtering to remove solvent, and drying to obtain defatted semen Ginkgo powder;
(3) extracting ginkgo protein: dissolving defatted semen Ginkgo powder in distilled water, adjusting pH to 10.0, stirring overnight, centrifuging, collecting supernatant, adjusting pH to 4.62, centrifuging again, removing supernatant, collecting precipitate, dialyzing the precipitate, and lyophilizing to obtain semen Ginkgo protein;
(4) enzymolysis: preparing 3% protein solution from semen Ginkgo protein, adjusting pH to 10.0, adding alkaline protease and enzyme activity to 4000U, and keeping the temperature at 50 deg.C for 4 hr;
(5) and (3) ultrafiltration: performing ultrafiltration with ultrafiltration membrane with molecular weight cutoff of 3000 Da, collecting ultrafiltration permeate, and lyophilizing;
(6) gel chromatography: further purifying the ultrafiltered substance with G-15 sephadex column, eluting with ultrapure water at flow rate of 1mL/min and sample concentration of 80 mg/mL, and collecting the chromatographic solution with retention time of 87.36-102.23 min;
(7) liquid chromatography separation of functional peptides: the sample was desalted and lyophilized and then redissolved in 0.1% trifluoroacetic acid solution. The C18 reversed phase chromatographic column was adopted, and the mobile phase a was 0.1% formic acid aqueous solution, and the mobile phase b was acetonitrile aqueous solution containing 0.1% formic acid (acetonitrile 84%). After the column was equilibrated with 95% solution a, a sample was applied by an autosampler, and the detection wavelength was 228nm and the flow rate was 1 mL/min. Collecting eluate with peak time of 44.23 min to obtain semen Ginkgo protein peptide solution with ACE inhibitory activity;
(8) the mass spectrometry analysis result shows that the amino acid sequence of the ginkgo protein peptide is as follows: threonine-asparagine-leucine-aspartate-tryptophan-Tyrosine (TNLDWY).
The foregoing is illustrative of the preferred embodiment of the present invention and is not to be construed as limiting thereof in any way, and any modifications or variations thereof that fall within the spirit of the invention are intended to be included within the scope thereof.
Claims (7)
1. The ginkgo nut protein peptide for reducing blood pressure is characterized by comprising the following components in parts by weight: consists of the following amino acid residues: threonine-asparagine-leucine-aspartic acid-tryptophan-tyrosine.
2. A preparation method of a ginkgo nut protein peptide for reducing blood pressure is characterized by comprising the following steps: comprises the following steps:
step 1; soaking and degreasing the ginkgo nut powder to obtain degreased ginkgo nut powder;
step 2: extracting protein from defatted ginkgo nut powder by an alkali-soluble acid precipitation method, dialyzing the obtained extracting solution, and freeze-drying to obtain ginkgo protein;
and step 3: preparing protein into aqueous solution, adding alkaline protease for enzymolysis, inactivating enzyme after enzymolysis, and centrifuging to obtain supernatant to obtain semen Ginkgo protease hydrolysate;
and 4, step 4: performing ultrafiltration treatment on the ginkgo protein hydrolysate, collecting ultrafiltration permeate and freeze-drying to obtain a ginkgo protein hydrolysate;
and 5: preparing semen Ginkgo protein hydrolysate into semen Ginkgo protein hydrolysate water solution, performing chromatography with dextran gel as chromatography medium, and collecting sample with retention time of 87.36-102.23 min;
step 6: desalting the sample obtained in the step 5, freeze-drying, dissolving in trifluoroacetic acid aqueous solution again, and then adopting a C18 reversed phase chromatographic column, wherein a mobile phase a is formic acid aqueous solution with the volume fraction of 0.1%, a mobile phase b is acetonitrile aqueous solution containing formic acid with the mass fraction of 0.1%, and the volume fraction of acetonitrile is 84%; after the chromatographic column is balanced by the solution a, a sample is loaded by an automatic sample injector, and the detection wavelength is 228 nm; collecting the eluate with peak time of 44.23 min to obtain semen Ginkgo protein peptide solution with blood pressure lowering effect; the mass spectrometry analysis result shows that the amino acid sequence of the ginkgo protein peptide is as follows: threonine-asparagine-leucine-aspartic acid-tryptophan-tyrosine.
3. The method for preparing a blood pressure lowering ginkgo nut protein peptide according to claim 2, wherein the method comprises the following steps: step 1, soaking the ginkgo nut powder in ethyl acetate for degreasing, performing suction filtration to remove a solvent after degreasing is finished, and drying to obtain degreased ginkgo nut powder; the particle size of the ginkgo nut powder is less than or equal to 40-80 meshes.
4. The method for preparing a blood pressure lowering ginkgo nut protein peptide according to claim 2, wherein the method comprises the following steps: and 2, dissolving the defatted ginkgo nut powder in distilled water, regulating the pH value to 10, stirring overnight, centrifuging, taking supernatant, regulating the pH value of the supernatant to 4.62, centrifuging again, removing the supernatant, taking precipitate, dialyzing the precipitate in distilled water, and freeze-drying to obtain the defatted ginkgo protein.
5. The method for preparing a blood pressure lowering ginkgo nut protein peptide according to claim 2, wherein the method comprises the following steps: in step 3, the defatted ginkgo protein is prepared into protein aqueous solution, the pH value is adjusted to 10, then alkaline protease is added, and the temperature is kept at 48-52 ℃ for 3.5-4.5 h.
6. The method for preparing a blood pressure lowering ginkgo nut protein peptide according to claim 2, wherein the method comprises the following steps: and 4, performing ultrafiltration treatment on the ginkgo biloba enzymolysis liquid by adopting an ultrafiltration membrane with the molecular weight cutoff of 3000 Da.
7. The method for preparing a blood pressure lowering ginkgo nut protein peptide according to claim 2, wherein the method comprises the following steps: in step 5, performing chromatography on the ginkgo biloba protein hydrolysate solution by using a G-15 sephadex column, collecting a sample with the retention time of 87.36-102.23min, and taking ultrapure water as an eluent, wherein the flow rate is 1mL/min, and the sample loading concentration is 80 mg/mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910434381.7A CN110183516B (en) | 2019-05-23 | 2019-05-23 | Preparation method of blood pressure lowering ginkgo nut protein peptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910434381.7A CN110183516B (en) | 2019-05-23 | 2019-05-23 | Preparation method of blood pressure lowering ginkgo nut protein peptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110183516A CN110183516A (en) | 2019-08-30 |
| CN110183516B true CN110183516B (en) | 2022-05-03 |
Family
ID=67717415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910434381.7A Active CN110183516B (en) | 2019-05-23 | 2019-05-23 | Preparation method of blood pressure lowering ginkgo nut protein peptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110183516B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112442112B (en) * | 2020-11-23 | 2021-10-15 | 东北农业大学 | Ginkgo protein source ACE inhibitory peptide composition and preparation method and application thereof |
| CN112940079B (en) * | 2021-03-19 | 2022-09-09 | 广州明创生物科技有限公司 | Rice antihypertensive peptide and enzymolysis preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103122022B (en) * | 2013-01-31 | 2015-04-22 | 陕西科技大学 | Angiotensin converting enzyme inhibitory peptide derived from bitter almond protein and preparation method thereof |
| CN105131083B (en) * | 2015-07-30 | 2018-07-10 | 陕西师范大学 | Flat almond peptide with angiotensin converting enzyme inhibition activity and preparation method thereof |
-
2019
- 2019-05-23 CN CN201910434381.7A patent/CN110183516B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110183516A (en) | 2019-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5854404A (en) | Antitumor substance extracted from grifola | |
| CN113215212B (en) | Soybean protein peptide with antioxidant and ACE (angiotensin converting enzyme) inhibiting functions and preparation method thereof | |
| CN110183516B (en) | Preparation method of blood pressure lowering ginkgo nut protein peptide | |
| AU666531B2 (en) | Processes for the preparation of amylase inhibitor | |
| CN110105430B (en) | Ginkgo nut protein peptide with angiotensin converting enzyme inhibitory activity and preparation method thereof | |
| CN110194786B (en) | Ginkgo nut protein peptide with ACE inhibitory activity and preparation method thereof | |
| CN110724178A (en) | Tuna white meat ACE inhibitory peptide and preparation method thereof | |
| CN110759965B (en) | Tuna red meat ACE inhibitory peptide and preparation method thereof | |
| CN115093456A (en) | Almond polypeptide with antioxidant activity and extraction method and application thereof | |
| CN110734947A (en) | preparation method of oat blood pressure lowering polypeptide | |
| DK145424B (en) | PROCEDURE FOR MANUFACTURING NITROGEN CONTAINING POLYSACCHARIDES WITH ANTI-TUMOR-EFFECTIVE | |
| CN112877390B (en) | Preparation method of functional alcohol-soluble sturgeon cartilage preparation | |
| CN112457377B (en) | Periplaneta americana polypeptide and application thereof | |
| CN112442112B (en) | Ginkgo protein source ACE inhibitory peptide composition and preparation method and application thereof | |
| WO2007066841A1 (en) | Yeast hydrolysate containing cyclo-his-pro and method for producing the same | |
| KR20220043706A (en) | Method for preparing hydrolyzate of Tenebrio molitor protein using NURUK and protease, and hydrolyzate of Tenebrio molitor protein with enhanced antioxidant content | |
| CN111825754A (en) | A polypeptide obtained from sesame protein and having blood pressure lowering and blood sugar lowering activities | |
| JP2004189748A (en) | New peptide used as angiotensin converting enzyme inhibitor, and preparation process thereof | |
| CN114044807B (en) | Mussel hypolipidemic oligopeptide for treating hyperlipidemia | |
| CN105648007B (en) | Preparation method of griseus shark cartilage protein antioxidant peptide | |
| CN113278670B (en) | Spirulina polypeptide and preparation method thereof | |
| CN114656522B (en) | Antioxidant peptide and preparation method and application thereof | |
| CN105648005B (en) | Preparation method of hammerhead shark cartilage protein antioxidant peptide | |
| CN106632599B (en) | clam antineoplastic enzymolysis oligopeptides | |
| CN115947781A (en) | Fermented wheat antihypertensive peptide, preparation method thereof, antihypertensive peptide combination and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |